Sugi Predict

Sugi Predict / Compounds / SCHEMBL1797371

SCHEMBL1797371

SCHEMBL1797371

CC(C(=O)O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 10/20 0.65
▸ AKR1C2 P52895 9/20 0.65
▸ PTGS2 P35354 5/20 0.55
▸ PTGS1 P23219 4/20 0.52
▸ LMNA P02545 2/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ CXCR1 P25024 2/20 0.52
▸ CXCR2 P25025 2/20 0.52
▸ ALB P02768 1/20 0.52
▸ ESR1 P03372 1/20 0.52
▸ ALOX5 P09917 1/20 0.52
▸ RARB P10826 1/20 0.52
▸ ADRB3 P13945 1/20 0.52
▸ NFKB1 P19838 1/20 0.52
▸ HTR2A P28223 1/20 0.52
▸ NR1I3 Q14994 1/20 0.52
▸ SLC22A6 Q4U2R8 1/20 0.52
▸ CXCL8 P10145 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ BLM P54132 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27621486 0.86 CES2 (0.52) AKR1C3AKR1C2CES2CES1PSEN1
SCHEMBL29009800 0.85 PTGS2 (0.52) AKR1C3AKR1C2PTGS2PTGS1LMNA
SCHEMBL11477759 0.83 AKR1C3 (0.59) AKR1C3AKR1C2PTGS2PTGS1SLC22A6
SCHEMBL59197 0.82 PTGS2 (0.74) AKR1C3AKR1C2PTGS2PTGS1LMNA
SCHEMBL19024394 0.82 EPHX1 (0.53) AKR1C3AKR1C2CES2CES1ACP3
SCHEMBL2055563 0.82 EPHX1 (0.53) AKR1C3AKR1C2CES2CES1ACP3
SCHEMBL27840939 0.82 AKR1C3 (0.52) AKR1C3AKR1C2PTGS2PTGS1LMNA
SCHEMBL28078623 0.82 PTGS2 (0.57) AKR1C3AKR1C2PTGS2PTGS1LMNA
SCHEMBL1716479 0.82 NR1H4 (0.71) AKR1C3AKR1C2PTGS2PTGS1LMNA
Ammonia Solution, Strong SCHEMBL11718703 0.81 AKR1C3 (0.58) AKR1C3AKR1C2PTGS2PTGS1SLC22A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 — — EP disclosed
CN-116113635-B Spiro compounds as melanocortin 4 receptor antagonists and uses thereof 辉瑞公司 2025-03-18 — — CN disclosed
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one PFIZER INC. (US) 2025-03-13 — — US disclosed
WO-2024233642-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2024-11-14 — — WO disclosed
EP-4249470-B1 METHOD FOR PREPARING ALPHA-AMINO ACIDS PHILIPPS UNIV MARBURG (DE) 2024-11-13 — — EP disclosed
EP-4161927-B9 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2024-11-06 — — EP disclosed
WO-2024165072-A1 POLYPEPTIDE COMPOUND AND USE THEREOF 成都纽瑞特医疗科技股份有限公司 2024-08-15 — — WO disclosed
EP-4161927-B1 SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER (US) 2024-08-07 — — EP disclosed
CN-118439917-A Preparation method of styrene compound 浙江工业大学 2024-08-06 — — CN disclosed
CN-118162197-A Heterogeneous catalyst for synthesizing phenylpropionic acid or phenylpropionic acid ester compound 中国石油化工股份有限公司 2024-06-11 — — CN disclosed
EP-1176956-A1 CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-02-06 — — EP disclosed
WO-2000067746-A1 CARBOXYLIC ACID DERIVATIVES THAT INHIBIT THE BINDING OF INTEGRINS TO THEIR RECEPTORS TEXAS BIOTECHNOLOGY CORPORATION (US) 2000-11-16 — — WO disclosed
US-6034106-A Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity MERCK & CO., INC. (US) 2000-03-07 — — US disclosed
EP-0906310-A4 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO INC (US) 1999-09-01 — — EP disclosed
EP-0906310-A1 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY Merck & Co., Inc. (US) 1999-04-07 — — EP disclosed
WO-1997046556-A1 OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1997-12-11 — — WO disclosed
US-5302752-A Acetic acid derivatives and their production ETHYL CORPORATION (US) 1994-04-12 — — US disclosed
EP-0426333-A2 Acetic acid derivatives and their production ETHYL CORPORATION (US) 1991-05-08 — — EP disclosed
CN-1033797-A The N-phenylalkylbenzamidefungicides fungicides LILLY CO ELI (US) 1989-07-12 — — CN disclosed
US-3936462-A CNS DEPRESSANT, ANALGESIC STERLING DRUG INC. (US) 1976-02-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084084-A1 Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one CSPP1, PRNP, RPLP2 AKR1C3 2978/4885AKR1C2 2334/4885PTGS2 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.